The United States Regenerative Medicine Market By Type (Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies, Tissue Engineered Products), By Material (Biologically Derived Material, Synthetic Material, Pharmaceuticals, Genetically Engineered Material), By Application (Musculoskeletal Disorders, Wound Care, Oncology, Ophthalmology, Neurology, Dermatology, Others), By Region, Competition, Forecast & Opportunities, 2026
United States regenerative medicine market is expected to witness robust CAGR until 2026. The United States regenerative medicine market is driven by the growing popularity of stem cell-based therapies.
Additionally, the use of regenerative medicines for treating chronic diseases, acute insults, and maladies is further propelling the market in the country.
The United States regenerative medicine market is segmented based on type, material, application, company, and region. Based on type, the market can be categorized into cell-based immunotherapy & cell therapy products, gene therapy products, tissue-engineered products, and others.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The cell-based immunotherapy & cell therapy products segment is expected to dominate the market during forecast years on account of the growing demand for cell-based immunotherapies and the establishment of cures act by the FDA to streamline the regenerative medicine market. The segment has the most promising future on account of its capability to restore the lost function of tissues and organs.
Based on application, the market can be fragmented into musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, dermatology, and others. The dermatology application segment is expected to hold a significant market share during the forecast years.
This can be attributed to the presence of easy grafting techniques for dermatological wounds and diseases.
Major players operating in the United States regenerative medicine market include Integra LifeSciences Holdings Corporation, Stryker Corporation, Amgen, Inc., AbbVie, Inc., Roche Diagnostics Corporation, Gilead Sciences, Inc., Astellas Pharma, Inc, bluebird bio, Inc., Medtronic USA, Inc., Organogenesis Holdings Inc., MiMedx Group Inc., Vericel Corporation and others. The companies are developing advanced technologies and launching new services in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new service developments. For instance, in 2017, Integra LifeSciences launched a new product, “Thin”- Integra dermal regeneration template single layer for dermal repair defects reconstruction in a single-step procedure.
Source: Finance. yahoo
